Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform

Human antibody-ribonuclease (RNase) fusion proteins, referred to as immunoRNases, have been proposed as an alternative to heterologous immunotoxins, without their immunogenicity and unspecific toxicity issues. In this study, we investigated if human pancreatic RNase will be suitable as effector comp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	mAbs 2014-03, Vol.6 (2), p.367-380
Hauptverfasser:	Schirrmann, Thomas, Frenzel, André, Linden, Lars, Stelte-Ludwig, Beatrix, Willuda, Jörg, Harrenga, Axel, Dübel, Stefan, Müller-Tiemann, Beate, Trautwein, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - immunology antibodies Antibodies, Catalytic - genetics Antibodies, Catalytic - metabolism Antigens, Neoplasm - immunology cancer therapy Cell Growth Processes - drug effects Colonic Neoplasms - drug therapy Colonic Neoplasms - immunology Cytotoxicity, Immunologic Endocytosis HEK293 Cells HT29 Cells human pancreatic RNase Humans IgG immunoglobulin Immunoglobulin G - genetics Immunoglobulin G - metabolism immunoRNase Immunotherapy - methods Immunotherapy - trends Lung Neoplasms - drug therapy Lung Neoplasms - immunology Molecular Targeted Therapy Pancreas - enzymology Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - metabolism Ribonucleases - genetics Ribonucleases - metabolism RNase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!